OM1, a Boston MA-based health technology company, raised $85M in funding.
The round was led by D1 Capital Partners, Kaiser Permanente, and Breyer Capital, with participation from General Catalyst (GC), Polaris Partners, Scale Venture Partners, 7wire Ventures, and Glikvest.
The company intends to use the funds to expand its real-world data cloud, clinical registries, and AI platform for real-world evidence and personalized medicine.
Led by CEO and founder Dr. Richard Gliklich, OM1 provides Health technology solutions focused on real-world outcomes for chronic conditions. The company partners with providers, medical societies, payers, and manufacturers to harness real-world data for advancing medical research, evaluating health outcomes, obtaining regulatory approvals, and personalizing treatment in chronic disease areas, such as dermatology, rheumatology, cardiology, gastroenterology, respiratory, neurosciences, and behavioral health. In addition to these efforts, OM1 develops artificial intelligence (AI) models and solutions for finding patients and predicting outcomes.
The company was founded in 2015 by the leadership team of Outcome Sciences, the pioneering real-world research company, which was acquired in 2011.
FinSMEs
17/07/2021